6.TREATMENT OUTCOME OF ATYPICAL FEMORAL FRACTURES
Main Article Content
Abstract
Objective: This study aims to evaluate the results of treatment of atypical femoral fractures to provide information for clinical practice.
Subjects and methods: Retrospective from August 2021 to August 2024, including patients diagnosed with atypical femoral fractures and surgery. Patients are diagnosed if they have at least 4 out of 5 criteria: mild trauma, transverse fracture, complete or incomplete fracture, minimal comminution, thickening of the lateral cortical bone. Exclusion criteria included bone fractures due to the tumor, severe systemic illness, and refusal to participate in the study.
Patient demographics, medication history, and fracture characteristics were recorded. Postoperative outcomes were assessed using X-rays at 3 months, 6 months and at the final follow-up visit. Functional outcomes were measured using the CAS score.
Results: The study included 27 atypical femoral fractures in 26 patients, with a follow-up of 10.7 months. Most patients were women (96.1%), with an average age of 69.3 years. A significant portion (73.1%) used alendronate. Fractures were located in the upper and middle third of the femur. 18 of 20 patients followed for at least 6 months achieved complete bone healing, with an average healing time of 8.1 months. Complications included 1 case of intramedullary nail breakage, 1 infection, and 2 non-unions.
Discussion: The study found that AFF predominantly affects older women, and related to prolonged Bisphosphonate use, particularly alendronate, is significant, and prolonged use increases fracture risk. Diagnostic imaging revealed specific fracture patterns and cortical thickening. Intramedullary nailing shown better healing times compared to plating. Functional recovery, assessed using CAS, indicated most patients regained satisfactory ambulation ability.
Conclusions: Atypical femoral fractures primarily affects elderly women with a history of Bisphosphonate use. Rehabilitation according to the CAS score is good. More attention needs to be paid to surgical technique to ensure bone union because the rate of non-union is high.
Article Details
Keywords
Atypical femoral fracture, Bisphosphonate, lateral cortex thickening
References
[2] Lee Y.K, Ahn S, Kim K.M, Suh C.S, Koo K.H, Incidence Rate of Atypical Femoral Fracture after Bisphosphonate Treatment in Korea, J Korean Med Sci, 2018, 33 (5): e38, Published 2018 Jan 29.
[3] Falotico G.G, Cunza J.F.F, Ferreira G.F, Oliveira V.O, Oksman D, Arliani G.G, Atypical femur fractures associated with chronic Bisphosphonate use: A case series with 66 patients, Rev Bras Ortop (Sao Paulo), 2021, 57 (5): 851-855, Published 2021 Mar 31.
[4] Black D.M, Geiger E.J, Eastell R et al, Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonate, N Engl J Med, 2020, 383 (8): 743-753.
[5] Lo J.C, Neugebauer R.S, Ettinger B et al, Risk of complete atypical femur fracture with Oral Bisphosphonate exposure beyond three years, BMC Musculoskelet Disord, 2020, 21 (1): 801, Published 2020 Dec 3.
[6] Gani L.U, Anthony N.F, Dacay L.M, Tan P.T, Chong L.R, King T.F.J, Characteristics of Bisphosphonate and non-Bisphosphonate related atypical femoral fracture in a South East Asian population - Secondary analysis, Bone, 2022, 162: 116455.
[7] Hagino H, Endo N, Yamamoto T et al, Treatment status and radiographic features of patients with atypical femoral fractures, J Orthop Sci, 2018, 23 (2): 316-320.
[8] LeBlanc E.S, Rosales A.G, Genant H.K et al, Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting, Osteoporos Int, 2019, 30 (6): 1287-1295.
[9] Adams A.L, Xue F, Chantra J.Q et al, Sensitivity and specificity of radiographic characteristics in atypical femoral fractures, Osteoporos Int, 2017, 28 (1): 413-417.
[10] Giusti A, Hamdy N.A, Papapoulos S.E, Atypical fractures of the femur and Bisphosphonate therapy: A systematic review of case/case series studies, Bone, 2010, 47 (2): 169-180.
[11] Teo B.J, Koh J.S, Goh S.K, Png M.A, Chua D.T, Howe T.S, Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on Bisphosphonate therapy, Bone Joint J, 2014, 96-B (5): 658-664.
[12] Canbek U, Akgun U, Aydogan N.H, Efficacy of bone-end intervention on fracture healing in Bisphosphonate-related atypical femoral fractures, Orthop Traumatol Surg Res, 2020, 106 (1): 77-83.
[13] Lee K.J, Yoo J.J, Oh K.J, et al, Surgical outcome of intramedullary nailing in patients with complete atypical femoral fracture: A multicenter retrospective study, Injury, 2017, 48 (4): 941-945.